Covington & Burling represented uniQure in the transaction. uniQure N.V. (NASDAQ: QURE), a leading gene therapy company, announced the closing of the sale of its global...
You must be a Standard 1 Year member to access this content.
Covington & Burling represented OrbiMed Advisors, LLC in the transaction. OrbiMed Advisors, LLC, a healthcare investment firm, announced a debt financing facility for up to $50...
You must be a Standard 1 Year member to access this content.
Covington & Burling advised OrbiMed on the deal. OrbiMed announced its $125 million debt financing with Verrica Pharmaceuticals, a dermatology therapeutics company developing medications for skin diseases...
You must be a Standard 1 Year member to access this content.
Covington advised Eisai in the transaction. Eisai Co., Ltd. signed its agreement to transfer all future economic rights for elacestrant (generic name), approved for the treatment for...
You must be a Standard 1 Year member to access this content.
Covington advised OrbiMed on the deal. OrbiMed acted as the lead investor in a $400 million senior secured term loan facility provided to Caris Life Sciences, a...
You must be a Standard 1 Year member to access this content.
Covington advised Insmed Incorporated on the deal while Fenwick represented Pharmakon. Walder Wyss advised the funds managed by Pharmakon Advisors, LP, BioPharma Credit and OrbiMed. Akin...
You must be a Standard 1 Year member to access this content.
Covington advised Marathon Asset Management LP on the deal. Marathon Asset Management LP announced a non-dilutive term loan for up to $100 million to Theratechnologies Inc. Marathon...
You must be a Standard 1 Year member to access this content.
